Alnylam Pharmaceuticals clinical trial pipeline

6 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 6 with minor changes only.

1. Minor

   ALN-4915 in Adult Healthy Volunteers

   Enrollment closed, study ongoing

   Also in this update: Final enrollment: 36 participants (planned 44)

   Alnylam Pharmaceuticals·Phase 1· NCT07535606· Registry history of NCT07535606 on ClinicalTrials.gov (opens the registry)

   Oct 15, 2026

2. Minor

   Mivelsiran · Early-Stage Down Syndrome-Associated Alzheimer's…Mivelsiran · Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)

   Trial sites expanded: 3 → 10 locations

   Alnylam Pharmaceuticals·Phase 2· NCT07636811· Registry history of NCT07636811 on ClinicalTrials.gov (opens the registry)

   Oct 13, 2026

3. Minor

   TRITON-PN · Nucresiran · Hereditary Transthyretin Amyloidosis…TRITON-PN · Nucresiran · Hereditary Transthyretin Amyloidosis With Polyneuropathy

   Trial sites expanded: 56 → 61 locations

   Alnylam Pharmaceuticals·Phase 3· NCT07223203· Registry history of NCT07223203 on ClinicalTrials.gov (opens the registry)

   Oct 8, 2026

4. Minor

   DemonsTTRate · Global, Observational, Multicenter, Long-term Study…DemonsTTRate · Global, Observational, Multicenter, Long-term Study · ATTR-CM in a Real-World Setting

   Trial sites expanded: 24 → 27 locations

   Alnylam Pharmaceuticals·Not specified· NCT07358078· Registry history of NCT07358078 on ClinicalTrials.gov (opens the registry)

   Oct 9, 2026

5. Minor

   ZENITH · Zilebesiran · Hypertension Not Adequately Controlled and…ZENITH · Zilebesiran · Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

   Start date moved earlier from Sep 22, 2025 to Sep 6, 2025

   And 1 more change in the last 30 days

   Alnylam Pharmaceuticals·Phase 3· NCT07181109· Registry history of NCT07181109 on ClinicalTrials.gov (opens the registry)

   Oct 15, 2026

6. Minor

   ALN-2232 · Obesity

   Study completion pushed from Mar 2, 2028 to Apr 28, 2028

   Alnylam Pharmaceuticals·Phase 1/2· NCT07463846· Registry history of NCT07463846 on ClinicalTrials.gov (opens the registry)

   Oct 13, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.